Hibberd

MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors

Retrieved on: 
Wednesday, December 16, 2020
Hibberd, Draft:MeMed Diagnostics

HAIFA, Israel, December 16, 2020 MeMed, a leader in host immune response-based solutions, today announced that Chris Hibberd has joined its Board of Directors.

Key Points: 
  • HAIFA, Israel, December 16, 2020 MeMed, a leader in host immune response-based solutions, today announced that Chris Hibberd has joined its Board of Directors.
  • Were delighted to welcome Chris Hibberd to our Board of Directors as we prepare for our next stage of growth, said Dr. Kfir Oved, MeMeds Co-founder, Chairman and CTO.
  • Chris brings deep domain expertise in building high medical value diagnostic franchises and will be a wonderful addition to our Board.
  • Chris joining our Board supports these efforts by further building the strategic leadership and operational excellence within it.

Nucleix Strengthens Leadership and Expands Footprint for U.S. Growth of Liquid Biopsy Development

Retrieved on: 
Monday, May 11, 2020
Oncology, Medical devices, Health, Other Health, General Health, Biotechnology, Medicine, Clinical medicine, Hibberd, Biopsy, Liquid biopsy

Mr. Hibberd added, The promise of liquid biopsy has been long discussed, but high-risk populations need solutions today that they can afford.

Key Points: 
  • Mr. Hibberd added, The promise of liquid biopsy has been long discussed, but high-risk populations need solutions today that they can afford.
  • Mr. Hibberd joins Nucleix with over 20 years of diagnostics and biopharmaceutical experience in company formation, clinical and business development and commercialization.
  • Prior to that, Mr. Hibberd was a manager at The Boston Consulting Group and a development engineer at Albright & Wilson Americas.
  • Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients.